Company intelligence / Profile preview

Béa Fertility

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Béa Fertility's at-home intracervical insemination (ICI) device delivers a clinically validated conception rate of 39.28% over 3 cycles in infertile patient populations, outperforming IUI rates in similar cohorts; more than 2,700 cycles have been delivered, 1,250 patients supported, and at least 29 live births documented as of June 2024[1][5].

Therapeutic areas: Women's Health
Modalities: DeviceDigital therapeutics
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Béa Fertility.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Béa Fertility.

Explore the full profile